JP5457632B2 - エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法 - Google Patents

エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法 Download PDF

Info

Publication number
JP5457632B2
JP5457632B2 JP2007518003A JP2007518003A JP5457632B2 JP 5457632 B2 JP5457632 B2 JP 5457632B2 JP 2007518003 A JP2007518003 A JP 2007518003A JP 2007518003 A JP2007518003 A JP 2007518003A JP 5457632 B2 JP5457632 B2 JP 5457632B2
Authority
JP
Japan
Prior art keywords
esomeprazole
sodium salt
sodium
crystalline form
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007518003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008503574A5 (enExample
JP2008503574A (ja
Inventor
マルティン・ブリーン
ウルスラ・ノーレランド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2008503574A publication Critical patent/JP2008503574A/ja
Publication of JP2008503574A5 publication Critical patent/JP2008503574A5/ja
Application granted granted Critical
Publication of JP5457632B2 publication Critical patent/JP5457632B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007518003A 2004-06-24 2005-06-20 エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法 Expired - Fee Related JP5457632B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58261704P 2004-06-24 2004-06-24
US60/582,617 2004-06-24
PCT/SE2005/000954 WO2006001753A1 (en) 2004-06-24 2005-06-20 New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012203798A Division JP2012246316A (ja) 2004-06-24 2012-09-18 エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法

Publications (3)

Publication Number Publication Date
JP2008503574A JP2008503574A (ja) 2008-02-07
JP2008503574A5 JP2008503574A5 (enExample) 2008-07-31
JP5457632B2 true JP5457632B2 (ja) 2014-04-02

Family

ID=35782078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007518003A Expired - Fee Related JP5457632B2 (ja) 2004-06-24 2005-06-20 エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法
JP2012203798A Pending JP2012246316A (ja) 2004-06-24 2012-09-18 エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012203798A Pending JP2012246316A (ja) 2004-06-24 2012-09-18 エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法

Country Status (12)

Country Link
US (1) US8658799B2 (enExample)
EP (1) EP1765806A1 (enExample)
JP (2) JP5457632B2 (enExample)
KR (2) KR20130038949A (enExample)
CN (3) CN1972928A (enExample)
AU (1) AU2005257709C1 (enExample)
BR (1) BRPI0512522A (enExample)
CA (1) CA2570795C (enExample)
HK (1) HK1197065A1 (enExample)
MX (1) MXPA06015031A (enExample)
NZ (1) NZ551970A (enExample)
WO (1) WO2006001753A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247566B2 (en) * 2005-06-08 2012-08-21 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
WO2007055178A1 (ja) * 2005-11-08 2007-05-18 Japan Health Sciences Foundation 細胞の分取方法、及び当該方法に用いる基材
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
ES2523921T3 (es) 2010-02-12 2014-12-02 Esteve Química, S.A. Procedimiento de preparación de la sal sódica de esomeprazol
CN102746272B (zh) * 2012-04-11 2014-06-25 江苏奥赛康药业股份有限公司 一种埃索美拉唑钠多晶型物及其制备方法和应用
CN102746273A (zh) * 2012-05-29 2012-10-24 江苏奥赛康药业股份有限公司 一种埃索美拉唑钠多晶型物及其在注射用药物中的应用
CN104031032B (zh) * 2014-07-04 2016-04-27 江苏奥赛康药业股份有限公司 一种埃索美拉唑钠化合物及其药物组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378974A (en) 1982-06-09 1983-04-05 Allis-Chalmers Corporation Start-up method for coal gasification plant
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
WO1995032957A1 (en) * 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
NL1007699C2 (nl) 1997-12-04 1999-06-09 Medisize Bv Beademingssysteem.
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
KR100712039B1 (ko) * 1999-08-26 2007-04-27 에이에이아이파머 인코포레이티드 알콕시로 치환된 벤즈이미다졸 화합물, 상기 화합물을포함하는 약학적 제제, 및 상기 화합물의 이용방법
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
AU2003262375A1 (en) 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
US7169793B2 (en) * 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
US20040235903A1 (en) 2002-10-22 2004-11-25 Khanna Mahavir Singh Amorphous form of esomeprazole salts
MXPA05005762A (es) * 2002-12-06 2005-08-16 Altana Pharma Ag Procedimiento para preparar compuestos activos opticamente puros.
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
US7683177B2 (en) 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole

Also Published As

Publication number Publication date
US8658799B2 (en) 2014-02-25
CN103121992A (zh) 2013-05-29
NZ551970A (en) 2010-01-29
HK1197065A1 (en) 2015-01-02
CN1972928A (zh) 2007-05-30
KR20130038949A (ko) 2013-04-18
KR20130140918A (ko) 2013-12-24
JP2012246316A (ja) 2012-12-13
AU2005257709A1 (en) 2006-01-05
AU2005257709B2 (en) 2008-11-13
CA2570795A1 (en) 2006-01-05
JP2008503574A (ja) 2008-02-07
AU2005257709C1 (en) 2011-02-24
WO2006001753A1 (en) 2006-01-05
CA2570795C (en) 2013-05-28
CN103772360A (zh) 2014-05-07
BRPI0512522A (pt) 2008-03-11
MXPA06015031A (es) 2007-02-08
EP1765806A1 (en) 2007-03-28
US20080039503A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
RU2184734C2 (ru) S-омепразол в нейтральной форме, способы его получения, фармацевтическая композиция, содержащая s-омепразол в нейтральной форме, и способ лечения связанного с желудочной кислотой состояния
JP2012246316A (ja) エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法
JP2002501529A (ja) Ｓ−オメプラゾールの新規な形態
WO2006001755A1 (en) A new esomeprazole sodium salt crystal modification
AU2006323245B2 (en) New process for the preparation of esomeprazole non-salt form
KR20070023757A (ko) 에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정변형의 제조를 위한 신규한 방법
HK1184464A (en) New process for preparation of crystal modifications for use in preparation of esomeprazole sodium salt
MX2008006935A (en) New process for the preparation of esomeprazole non-salt form
MXPA99005661A (en) A novel compound form
HK1022909B (en) A novel compound form

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120918

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140110

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees